Background and purpose: Glioma is the most common primary tumor of the central nervous system. This study aimed to investigate the clinical significance of cerebrospinal fluid (CSF) and plasma D-dimer levels and the relation with ventricular metastasis (VM) and spinal cord metastasis (SCM) of glioma. Methods: The CSF and plasma D-dimer levels were measured in 83 glioma patients. The glioma patients were divided into unrelapsed group and relapse group; parenchyma group
VM group and SCM group; primary spinal cord metastasis (PSCM) group and secondary spinal cord metastasis (SSCM) group according to the clinical characteristics. We investigated the relationship between the levels of CSF or plasma D-dimer and spinal cord metastasis or ventricular metastasis of glioma. Results: The CSF D-dimer level of relapse group was significantly higher than that of unrelapsed group (P=0.000 3). The CSF D-dimer level of SCM group was significantly higher than that of VM group (P=0.001 5). The CSF D-dimer levels of VM and SCM groups were significantly higher compared with parenchyma group (P=0.000 1
P=0.000 3). The CSF D-dimer level of SSCM group was significantly higher than that of PSCM group (P=0.000 5). The CSF D-dimer levels of VM (P=0.0001) and SCM groups (P=0.005 0) were significantly reduced after chemotherapy. The plasma D-dimer level of SCM group was significantly higher compared with VM group (P=0.023 5) and parenchyma group (P=0.000 5). There was no significant difference in the plasma D-dimer level between unrelapsed and relapse groups (P=0.371 8) or PSCM and SSCM groups (P=0.059 2). The plasma D-dimer levels of VM group (P=0.182 4) and SCM group (P=0.093 3) did not decrease significantly after chemotherapy. In the receiver operating characteristic (ROC) curve
the optimal cut-off points for CSF and plasma D-dimer levels were found to be 69 and 219 ng/mL in glioma patients with sensitivity and specificity of 86.75 %
94.12% and 34.94%
94.12%
respectively. Conclusion: D-dimer might be an important clinical marker for spinal cord metastasis or ventricular metastasis and response evaluation in glioma.
Retrospective study on MGMT methylation status and its clinical significance in gliomas
WTAP promotes proliferation and aerobic glycolysis via regulating m6A modification of BMI1 mRNA
Screening recurrent glioblastoma-related genes and analyzing their gene expressions in association with clinicopathological parameters and prognosis
Effect ofCHKAgene silencing on biological behavior of glioma cell and its mechanism
The prognostic value of microfluidic core technology in detecting circulating tumor cells in brain glioma
Related Author
Xiaoli ZHU
Qianming BAI
Min REN
Tian XUE
Xiaoyan ZHOU
Heng CHANG
Jing ZHANG
Liqing JIA
Related Institution
Department of Pathology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University; Fudan University Cancer Institute
Department of Neurosurgery, Wu’an First People’s Hospital
Department of Neurosurgery, the First Affiliated Hospital of Nanyang Medical College
Department of Neuro-oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University